
浏览全部资源
扫码关注微信
1.重庆医科大学附属儿童医院儿研所、国家儿童健康与疾病临床医学研究中心、儿童发育疾病研究教育部重点实验室、 儿科学重庆市重点实验室,重庆 400014
2.重庆医科大学附属儿童医院检验科,重庆 400014
3.重庆医科大学附属儿童医院心血管科(内科),重庆 400014
陈芸霞,Email:1667655274@qq.com,研究方向:心肌损伤。
朱 静,Email:jingzhu@cqmu.edu.cn。
收稿:2024-01-12,
修回:2024-04-09,
录用:2024-04-11,
纸质出版:2024-09-28
移动端阅览
陈芸霞,邓洪荣,刘蕙文,等.两种H9C2心肌细胞氧化损伤模型的比较[J].重庆医科大学学报,2024,49(9):1079-1085.
Cheng Yunxia,Deng Hongrong,Liu Huiwen,et al.Comparison of two models of oxidative damage in H9C2 cardiomyocytes[J].Journal of Chongqing Medical University,2024,49(9):1079-1085.
陈芸霞,邓洪荣,刘蕙文,等.两种H9C2心肌细胞氧化损伤模型的比较[J].重庆医科大学学报,2024,49(9):1079-1085. DOI: 10.13406/j.cnki.cyxb.003585.
Cheng Yunxia,Deng Hongrong,Liu Huiwen,et al.Comparison of two models of oxidative damage in H9C2 cardiomyocytes[J].Journal of Chongqing Medical University,2024,49(9):1079-1085. DOI: 10.13406/j.cnki.cyxb.003585.
目的
2
探讨低氧、低糖及血清剥夺(glucose and serum deprivation under hypoxia(1% O
2
),GSDH)处理与H
2
O
2
处理在构建H9C2心肌细胞氧化损伤模型中的应用价值。
方法
2
培养 H9C2 心肌细胞,当细胞生长状态良好时,用低氧(1% O
2
)、低糖(1.0 g/L)及血清剥夺联合处理或200 μmol/L的H
2
O
2
作用于心肌细胞24 h。采用CCK8实验检测细胞增殖能力;通过细胞凋亡试剂(annexinV-FITC/PI)、Hoechst染色检测细胞凋亡;细胞活性氧(reactive oxygen species,ROS)检测细胞氧化应激水平;BODIPY检测细胞脂质过氧化水平;过碘酸雪夫(periodic acid-schiff stain,PAS)染色检测细胞糖原合成能力;线粒体膜电位检测试剂(mitochondrial membrane potential assay kit with JC-1,JC-1)染色检测线粒体膜电位水平;Western blot检测能量代谢相关分子AMP依赖的蛋白激酶(Adenosine 5’-monophosphate(AMP)-activated protein kinase,AMPK)及氧化应激相关分子NAD(P)H醌脱氢酶1(NAD(P)H quinone dehydrogenase 1,NQO-1)、血红素氧合酶1(heme oxygenase-1,HO-1)蛋白表达水平。
结果
2
与空白组比较,GSDH处理组与H
2
O
2
处理组的心肌细胞存活率均降低,差异均有统计学意义(
P
<
0.05)。与空白组相比,GSDH处理与H
2
O
2
处理都增加了心肌细胞的凋亡水平、ROS和脂滴堆积水平增高、糖原消耗量增加且线粒体膜电位降低。但相比于H
2
O
2
处理组,GSDH处理组的细胞糖原消耗增多更明显,脂滴堆积也更明显,并且AMPK磷酸化水平显著降低。
结论
2
低氧、低糖及GSDH处理与H
2
O
2
处理均能造成H9C2心肌细胞氧化损伤,但相比于H
2
O
2
处理组,GSDH处理组的效果更符合体内心肌损伤时的能量代谢转变,有望作为一种更简单便捷的心肌氧化损伤模型应用于科研。
Objective
2
To investigate the value of glucose and serum deprivation under hypoxia(1% O
2
)(GSDH) treatment and H
2
O
2
treatment in establishing a model of oxidative injury in H9C2 cardiomyocytes.
Methods
2
H9C2 cardiomyocytes were cultured,and when the cardiomyocytes were in good growth conditions,they were treated with the combination of low oxygen(1% O
2
),low glucose(1.0 g/L),and serum deprivation or H
2
O
2
200 μmol/L alone for 24 hours. CCK8 assay was sued to measure the proliferation ability of cells;the apoptosis reagent(AnnexinV-FITC/PI) and Hoechst staining were used to measure cell apoptosis;reactive oxygen species(ROS) was used to measure the level of oxidative stress;BODIPY testing was used to measure the level of lipid peroxidation in cells;periodic acid-Schiff staining was used to measure the ability for glycogen synthesis;mitochondrial membrane potential assay kit with JC-1 staining was used to measure mitochondrial membrane potential;Western blot was used to measure the protein expression levels of the energy metabolism-related molecule AMP-activated protein kinase(AMPK) and the oxidative stress-related molecules NAD(P)H quinone dehydrogenase 1(NQO-1) and heme oxygenase-1(HO-1).
Results
2
Compared with the blank group,both the GSDH treatment group and the H
2
O
2
treatment group had a significant reduction in the viability of cardiomyocytes(
P
<
0.05). Compared with the blank group,both GSDH treatment and H
2
O
2
treatment increased the levels of cardiomyocyte apoptosis,ROS and lipid droplet accumulation,and glycogen consumption,with a reduction in mitochondrial membrane potential in cardiomyocytes. However,compared
with the H
2
O
2
treatment group,the GSDH treatment group showed significantly greater increases in glycogen consumption and lipid droplet accumulation and a significant reduction in AMPK phosphorylation.
Conclusion
2
Both GSDH treatment and H
2
O
2
treatment can cause oxidative injury to H9C2 cardiomyocytes,but compared with H
2
O
2
treatment,the effect of GSDH treatment is more in line with the energy metabolism transition during myocardial injury
in vivo
,and therefore,it is expected to be used as a simpler and more convenient model of oxidative injury to cardiac myocardium for scientific research.
Townsend N , Kazakiewicz D , Lucy Wright F , et al . Epidemiology of cardiovascular disease in Europe [J ] . Nat Rev Cardiol , 2022 , 19 ( 2 ): 133 - 143 .
Lolley R , Forman DE . Cardiac rehabilitation and survival for ischemic heart disease [J ] . Curr Cardiol Rep , 2021 , 23 ( 12 ): 184 .
Karwi QG , Sun QY , Lopaschuk GD . The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity [J ] . Cells , 2021 , 10 ( 11 ): 3259 .
Masoli JAH , Mensah E , Rajkumar C . Age and ageing cardiovascular collection:blood pressure,coronary heart disease and heart failure [J ] . Age Ageing , 2022 , 51 ( 8 ): afac179 .
Carley AN , Maurya SK , Fasano M , et al . Short-chain fatty acids outpace ketone oxidation in the failing heart [J ] . Circulation , 2021 , 143 ( 18 ): 1797 - 1808 .
Lopaschuk GD , Karwi QG , Tian R , et al . Cardiac energy metabolism in heart failure [J ] . Circ Res , 2021 , 128 ( 10 ): 1487 - 1513 .
Ranjbarvaziri S , Kooiker KB , Ellenberger M , et al . Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy [J ] . Circulation , 2021 , 144 ( 21 ): 1714 - 1731 .
Zhao MM , Wei HR , Li CZ , et al . Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy [J ] . Nat Commun , 2022 , 13 ( 1 ): 1757 .
Chen Z , Jin ZX , Cai JJ , et al . Energy substrate metabolism and oxidative stress in metabolic cardiomyopathy [J ] . J Mol Med , 2022 , 100 ( 12 ): 1721 - 1739 .
Zhuang LF , Jia KN , Chen C , et al . DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics [J ] . Circulation , 2022 , 145 ( 11 ): 829 - 846 .
Murashige D , Jang C , Neinast M , et al . Comprehensive quantification of fuel use by the failing and nonfailing human heart [J ] . Science , 2020 , 370 ( 6514 ): 364 - 368 .
Dambrova M , Zuurbier CJ , Borutaite V , et al . Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury [J ] . Free Radic Biol Med , 2021 , 165 : 24 - 37 .
Li Y , Ma Y , Dang QY , et al . Assessment of mitochondrial dysfunction and implications in cardiovascular disorders [J ] . Life Sci , 2022 , 306 : 120834 .
Wang X , Chen XX , Zhou WQ , et al . Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways [J ] . Acta Pharm Sin B , 2022 , 12 ( 2 ): 708 - 722 .
Feng YN , Zhang YY , Xiao H . AMPK and cardiac remodelling [J ] . Sci China Life Sci , 2018 , 61 ( 1 ): 14 - 23 .
Steinberg GR , Hardie DG . New insights into activation and function of the AMPK [J ] . Nat Rev Mol Cell Biol , 2023 , 24 ( 4 ): 255 - 272 .
Cruz AM , Partridge KM , Malekizadeh Y , et al . Brain permeable AMP-activated protein kinase activator R481 raises glycaemia by autonomic nervous system activation and amplifies the counterregulatory response to hypoglycaemia in rats [J ] . Front Endocrinol , 2021 , 12 : 697445 .
Spaulding HR , Yan Z . AMPK and the adaptation to exercise [J ] . Annu Rev Physiol , 2022 , 84 : 209 - 227 .
Popov SV , Mukhomedzyanov AV , Voronkov NS , et al . Regulation of autophagy of the heart in ischemia and reperfusion [J ] . Apoptosis , 2023 , 28 ( 1/2 ): 55 - 80 .
Yao MR , Wang ZR , Jiang LY , et al . Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway [J ] . Biomed Pharmacother , 2022 , 153 : 113498 .
Fouqueray P , Bolze S , Dubourg J , et al . Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease:a phase 1b study [J ] . Cell Rep Med , 2021 , 2 ( 12 ): 100474 .
Zhang Q , Liu SD , Zhang CS , et al . AMPK directly phosphorylates TBK1 to integrate glucose sensing into innate immunity [J ] . Mol Cell , 2022 , 82 ( 23 ): 4519 - 4536 .
Midha AD , Zhou YY , Queliconi BB , et al . Organ-specific fuel rewiring in acute and chronic hypoxia redistributes glucose and fatty acid metabolism [J ] . Cell Metab , 2023 , 35 ( 3 ): 504 - 516 .
Nielsen R , Møller N , Gormsen LC , et al . Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients [J ] . Circulation , 2019 , 139 ( 18 ): 2129 - 2141 .
0
浏览量
11
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621